Wechselwirkungen · Viread
Viread 123 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-110500 · Präparat HOS-093385
10 Medicinal product by Effects on drug levels Recommendation concerning therapeutic areas Mean percent change in AUC, co-administration with 245 mg (dose in mg) Cmax, Cmin tenofovir disoproxil Ledipasvir/Sofosbuvir Ledipasvir: Increased plasma concentrations (90 mg/400 mg q.d.) + AUC: ↔ of tenofovir resulting from Darunavir/Ritonavir Cmax: ↔ co-administration of tenofovir (800 mg q.d./100 mg q.d.) + Cmin: ↔ disoproxil, ledipasvir/sofosbuvir Emtricitabine/Tenofovir disoproxil and darunavir/ritonavir may (200 mg/245 mg q.d.)1 Sofosbuvir: increase adverse reactions related AUC: ↓ 27% to tenofovir disoproxil, including Cmax: ↓ 37% renal disorders. The safety of tenofovir disoproxil when used GS-3310072: with ledipasvir/sofosbuvir and a AUC: ↔ pharmacokinetic enhancer (e.g. Cmax: ↔ ritonavir or cobicistat) has not Cmin: ↔ been established.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) sofosbuvir (HOS-108928) ledipasvir (HOS-110493) cobicistat (HOS-088111) darunavir (HOS-086181) ritonavir (HOS-084521) emtricitabine (HOS-085840)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-02-29T16:34:00Z · SHA-256 ab427f9266bbb81991653ebf14729e0d885f7cb9014fd47e3b3ee4fc69589ee0 · Passage 087a97d32c6196144fac42069c01c95f98b657dbaf4644b79b530f187480c3be · Zeichen 10060–11640 im Abschnitt